Crossmark

1060 DF9001, an EGFR targeted immune engager, stimulates innate and adaptive anti-tumor immunity with a distinctive safety profile

Crossref DOI link: https://doi.org/10.1136/jitc-2024-SITC2024.1060

Published Online: 2024-11-05

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Bigelow, Mitchell

LaCroix, Colin

Chawla, Mehma Kaur

Fagiani, Zachary

Basinski, Sara

Kirby, Patrick

Hicks, Stuart

Juo, Sean

Grinberg, Asya

Wagtmann, Nicolai

Cheung, Ann
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05597839 at ClinicalTrials.gov

Documents that mention this clinical trial

1060 DF9001, an EGFR targeted immune engager, stimulates innate and adaptive anti-tumor immunity with a distinctive safety profile
https://doi.org/10.1136/jitc-2024-sitc2024.1060
License Information

License valid from 2024-10-28